| pubmed-article:17240478 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C0162836 | lld:lifeskim |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C0205374 | lld:lifeskim |
| pubmed-article:17240478 | lifeskim:mentions | umls-concept:C1707491 | lld:lifeskim |
| pubmed-article:17240478 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17240478 | pubmed:dateCreated | 2007-3-19 | lld:pubmed |
| pubmed-article:17240478 | pubmed:abstractText | Hidradenitis suppurativa (HS) is a chronic and debilitating disorder. Despite its significant prevalence, few reports of therapeutic studies are available. Recent case studies have reported the efficacy of antitumor necrosis factor monoclonal antibodies in treating the condition. In the study presented here, we assessed the safety and efficacy of infliximab in a series of patients with severe HS. | lld:pubmed |
| pubmed-article:17240478 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17240478 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17240478 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17240478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17240478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17240478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17240478 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17240478 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:17240478 | pubmed:issn | 1097-6787 | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:MorelPatriceP | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:AllezMatthieu... | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:FardetLaurenc... | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:DupuyAlainA | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:BachelezHervé... | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:LebbéCelesteC | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:KerobDelphine... | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:BegonEdouardE | lld:pubmed |
| pubmed-article:17240478 | pubmed:author | pubmed-author:LevyAnnabelle... | lld:pubmed |
| pubmed-article:17240478 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17240478 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:17240478 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17240478 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17240478 | pubmed:pagination | 624-8 | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:meshHeading | pubmed-meshheading:17240478... | lld:pubmed |
| pubmed-article:17240478 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17240478 | pubmed:articleTitle | Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. | lld:pubmed |
| pubmed-article:17240478 | pubmed:affiliation | Department of Dermatology, Hospital Saint-Antoine, Paris, France. laurence.fardet@sat.aphp.fr | lld:pubmed |
| pubmed-article:17240478 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17240478 | lld:pubmed |
